vs
Side-by-side financial comparison of Ensysce Biosciences, Inc. (ENSC) and INNSUITES HOSPITALITY TRUST (IHT). Click either name above to swap in a different company.
Ensysce Biosciences, Inc. is the larger business by last-quarter revenue ($1.9M vs $1.8M, roughly 1.0× INNSUITES HOSPITALITY TRUST). INNSUITES HOSPITALITY TRUST runs the higher net margin — -19.8% vs -147.0%, a 127.3% gap on every dollar of revenue. On growth, Ensysce Biosciences, Inc. posted the faster year-over-year revenue change (44.4% vs -1.1%). Over the past eight quarters, Ensysce Biosciences, Inc.'s revenue compounded faster (107.9% CAGR vs 2.1%).
Ensysce Biosciences, Inc. is a clinical-stage biotechnology firm specializing in developing innovative prodrug therapies for pain management and oncology indications. Its proprietary platform is designed to reduce opioid abuse risks while enhancing treatment efficacy, targeting global healthcare and pharmaceutical markets with a focus on unmet clinical needs.
InnSuites Hospitality Trust, based in Phoenix, Arizona, is a real estate investment trust that invests in lodging. While it is formed as a real estate investment trust, it is not classified as a real estate investment trust for tax purposes. The company owns interests in two hotels, operates three hotels, provides management for three hotels, and licenses its InnSuites trademark for five hotels. The company's hotel ownership interests are a 51.01% interest in the Best Western InnSuites Tucson...
ENSC vs IHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.9M | $1.8M |
| Net Profit | $-2.8M | $-356.9K |
| Gross Margin | — | — |
| Operating Margin | -147.8% | -10.0% |
| Net Margin | -147.0% | -19.8% |
| Revenue YoY | 44.4% | -1.1% |
| Net Profit YoY | 22.3% | -29.1% |
| EPS (diluted) | $-0.51 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9M | $1.8M | ||
| Q3 25 | $493.1K | $1.8M | ||
| Q2 25 | $1.4M | $2.2M | ||
| Q1 25 | $1.3M | $1.6M | ||
| Q4 24 | $1.3M | $1.8M | ||
| Q3 24 | $3.4M | $1.8M | ||
| Q2 24 | — | $7.5M | ||
| Q1 24 | — | $1.7M |
| Q4 25 | $-2.8M | $-356.9K | ||
| Q3 25 | $-3.7M | $-391.2K | ||
| Q2 25 | $-1.7M | $-121.0K | ||
| Q1 25 | $-1.9M | $-595.2K | ||
| Q4 24 | $-3.6M | $-276.4K | ||
| Q3 24 | $661.8K | $-370.9K | ||
| Q2 24 | — | $-148.6K | ||
| Q1 24 | — | $-113.0K |
| Q4 25 | -147.8% | -10.0% | ||
| Q3 25 | -758.7% | -13.3% | ||
| Q2 25 | -127.6% | 10.1% | ||
| Q1 25 | -149.1% | -30.9% | ||
| Q4 24 | -274.3% | -7.1% | ||
| Q3 24 | 18.9% | -15.5% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | -35.3% |
| Q4 25 | -147.0% | -19.8% | ||
| Q3 25 | -756.3% | -21.7% | ||
| Q2 25 | -126.4% | -5.5% | ||
| Q1 25 | -147.4% | -36.4% | ||
| Q4 24 | -273.4% | -15.1% | ||
| Q3 24 | 19.4% | -20.2% | ||
| Q2 24 | — | -2.0% | ||
| Q1 24 | — | -6.5% |
| Q4 25 | $-0.51 | $-0.04 | ||
| Q3 25 | $-1.29 | $-0.04 | ||
| Q2 25 | $-0.79 | $-0.01 | ||
| Q1 25 | $-1.39 | $-0.07 | ||
| Q4 24 | $-0.89 | $-0.03 | ||
| Q3 24 | $1.00 | $-0.04 | ||
| Q2 24 | — | $-0.02 | ||
| Q1 24 | — | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.3M | — |
| Total DebtLower is stronger | — | $11.3M |
| Stockholders' EquityBook value | $3.2M | $3.6M |
| Total Assets | $7.5M | $13.9M |
| Debt / EquityLower = less leverage | — | 3.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.3M | — | ||
| Q3 25 | $1.7M | — | ||
| Q2 25 | $2.2M | — | ||
| Q1 25 | $3.1M | — | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $4.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.3M |
| Q4 25 | — | $11.3M | ||
| Q3 25 | — | $11.2M | ||
| Q2 25 | — | $10.5M | ||
| Q1 25 | — | $10.7M | ||
| Q4 24 | — | $10.3M | ||
| Q3 24 | — | $10.0M | ||
| Q2 24 | — | $9.7M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $3.2M | $3.6M | ||
| Q3 25 | $1.2M | $4.0M | ||
| Q2 25 | $3.4M | $4.4M | ||
| Q1 25 | $3.0M | $4.6M | ||
| Q4 24 | $3.7M | $5.2M | ||
| Q3 24 | $6.9M | $5.5M | ||
| Q2 24 | — | $6.0M | ||
| Q1 24 | — | $6.2M |
| Q4 25 | $7.5M | $13.9M | ||
| Q3 25 | $3.2M | $14.2M | ||
| Q2 25 | $5.6M | $14.0M | ||
| Q1 25 | $4.6M | $14.2M | ||
| Q4 24 | $5.6M | $15.0M | ||
| Q3 24 | $9.4M | $15.1M | ||
| Q2 24 | — | $15.3M | ||
| Q1 24 | — | $15.7M |
| Q4 25 | — | 3.12× | ||
| Q3 25 | — | 2.82× | ||
| Q2 25 | — | 2.37× | ||
| Q1 25 | — | 2.34× | ||
| Q4 24 | — | 1.98× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | — | 1.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.5M | $-145.1K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.5M | $-145.1K | ||
| Q3 25 | $-1.9M | $-153.0K | ||
| Q2 25 | $-2.7M | $279.8K | ||
| Q1 25 | $-1.7M | $-1.1M | ||
| Q4 24 | $-764.1K | $-146.7K | ||
| Q3 24 | $-1.0M | $-44.6K | ||
| Q2 24 | — | $-459.4K | ||
| Q1 24 | — | $1.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENSC
Segment breakdown not available.
IHT
| Room | $1.7M | 96% |
| Other | $74.1K | 4% |
